XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Other Operating Liabilities
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Other Operating Liabilities of $296.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $4.98M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$4.68M, a 445.10% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $2.33M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $297.00K, a 36.67% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2025 was $3.72M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2024 was -$1.07M, a 131.59% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2023 was $3.39M, a 35.34% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in other operating liabilities for fiscal 2022 was $2.51M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $296.00K 10-Q · filed 2026-08-06 | $2.63M derived: sum of 3 quarters · filed 2026-08-06 | $2.93M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$4.68M 10-Q · filed 2026-05-07 | -$2.35M derived: sum of 2 quarters · filed 2026-05-07 | -$2.05M derived: sum of 3 quarters · filed 2026-05-07 | -$2.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.63M derived: sum of 2 quarters · filed 2026-03-02 | $2.37M derived: sum of 3 quarters · filed 2026-08-06 | $3.72M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $31.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.39M 10-Q · filed 2025-11-06 | -$1.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$266.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.09M 10-Q · filed 2026-08-06 | -$2.28M derived: sum of 3 quarters · filed 2026-08-06 | -$1.81M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.36M 10-Q · filed 2026-05-07 | -$2.01M derived: sum of 2 quarters · filed 2026-05-07 | -$1.54M derived: sum of 3 quarters · filed 2026-05-07 | -$515.00K derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$2.90M derived: sum of 2 quarters · filed 2026-03-02 | -$1.87M derived: sum of 3 quarters · filed 2026-03-02 | -$1.07M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.50M derived: sum of 2 quarters · filed 2025-11-06 | $2.30M 10-Q · filed 2025-11-06 | $4.25M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.83M 10-Q · filed 2025-08-07 | $3.78M derived: sum of 3 quarters · filed 2026-03-02 | $3.54M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-08 | $2.75M derived: sum of 2 quarters · filed 2026-03-02 | $2.51M derived: sum of 3 quarters · filed 2026-03-02 | $4.09M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2023-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.71M derived: sum of 2 quarters · filed 2026-03-02 | $3.29M derived: sum of 3 quarters · filed 2026-03-02 | $3.39M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | -$240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.34M derived: sum of 2 quarters · filed 2024-11-08 | $1.44M 10-Q · filed 2024-11-08 | $1.12M 10-Q · filed 2023-11-09 | $6.44M derived: sum of 4 quarters · filed 2025-03-06 | |||
| 2023-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.68M 10-Q · filed 2024-08-08 | $992.00K 10-Q · filed 2023-08-08 | $6.68M derived: sum of 3 quarters · filed 2025-03-06 | $5.26M derived: sum of 4 quarters · filed 2025-03-06 | |||
| 2023-03-31 | $99.00K 10-Q · filed 2024-05-09 | $5.10M derived: sum of 2 quarters · filed 2025-03-06 | $3.68M derived: sum of 3 quarters · filed 2025-03-06 | $5.29M derived: sum of 4 quarters · filed 2025-03-06 | ||||
| 2022-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.58M derived: sum of 2 quarters · filed 2025-03-06 | $5.19M derived: sum of 3 quarters · filed 2025-03-06 | $2.51M 10-K · filed 2025-03-06 | ||||
| 2022-09-30 | -$1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $190.00K derived: sum of 2 quarters · filed 2023-11-09 | -$2.50M 10-Q · filed 2023-11-09 | -$2.26M 10-Q · filed 2022-11-09 | -$3.75M derived: sum of 4 quarters · filed 2024-03-06 | |||
| 2022-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.08M 10-Q · filed 2023-08-08 | -$992.00K 10-Q · filed 2022-08-10 | -$2.33M derived: sum of 3 quarters · filed 2024-03-06 | -$2.31M derived: sum of 4 quarters · filed 2024-03-06 | |||
| 2022-03-31 | -$2.69M 10-Q · filed 2023-05-09 | -$8.03M 10-Q · filed 2022-05-11 | -$3.94M derived: sum of 2 quarters · filed 2024-03-06 | -$3.92M derived: sum of 3 quarters · filed 2024-03-06 | -$2.38M derived: sum of 4 quarters · filed 2024-03-06 | |||
| 2021-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$1.23M derived: sum of 2 quarters · filed 2024-03-06 | $307.00K derived: sum of 3 quarters · filed 2024-03-06 | -$1.19M 10-K · filed 2024-03-06 | -$1.44M 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.56M derived: sum of 2 quarters · filed 2022-11-09 | $62.00K 10-Q · filed 2022-11-09 | $674.00K derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $43.00K 10-Q · filed 2022-08-10 | $655.00K derived: sum of 3 quarters · filed 2022-08-10 | |||||
| 2021-03-31 | -$1.49M 10-Q · filed 2022-05-11 | -$882.00K derived: sum of 2 quarters · filed 2022-05-11 | ||||||
| 2020-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $3.20M 10-K · filed 2022-03-11 | ||||||
| 2020-09-30 | $2.59M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |